| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 9.942 | 24.537 | 35.065 | 40.869 | 47.135 | 58.833 | 58.927 |
| Total Income - EUR | - | - | - | 9.942 | 24.537 | 35.065 | 40.869 | 47.135 | 58.833 | 58.927 |
| Total Expenses - EUR | - | - | - | 10.201 | 6.256 | 6.602 | 13.898 | 11.300 | 23.409 | 30.256 |
| Gross Profit/Loss - EUR | - | - | - | -259 | 18.281 | 28.463 | 26.971 | 35.835 | 35.423 | 28.672 |
| Net Profit/Loss - EUR | - | - | - | -557 | 17.545 | 27.489 | 25.892 | 34.740 | 34.987 | 27.051 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Lorydiab Med S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 724 |
| Current Assets | - | - | - | 567 | 17.290 | 43.950 | 58.420 | 39.469 | 42.382 | 29.711 |
| Inventories | - | - | - | 0 | 324 | 283 | 440 | 0 | 0 | 0 |
| Receivables | - | - | - | 161 | 2.456 | 2.964 | 4.572 | 5.786 | 21.282 | 10.202 |
| Cash | - | - | - | 406 | 14.510 | 40.703 | 53.407 | 33.682 | 21.101 | 19.508 |
| Shareholders Funds | - | - | - | -514 | 17.041 | 27.926 | 48.954 | 37.207 | 41.757 | 28.368 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 1.081 | 249 | 16.023 | 9.467 | 2.262 | 626 | 2.067 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Lorydiab Med S.r.l.